Researchers found that a new drug called CTX-8371 shows promise for treating advanced cancers that have not responded to previous therapies. This drug targets two proteins involved in immune response, PD-1 and PD-L1, and has demonstrated significant effects in patients with triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer. Notably, some patients experienced deep and lasting reductions in their tumors.

This discovery could be a game-changer for people facing these challenging cancers. In the study, 33% of patients at the highest doses saw a positive response, with one patient achieving over a 90% reduction in tumor size. The effects were not only immediate; some patients maintained these responses for over 10 months. With no severe side effects reported, CTX-8371 could offer a new, well-tolerated option for those who have exhausted other treatments.

The research is still in the early stages, as this is a Phase 1 trial involving a small group of 15 patients. While the initial results are encouraging, more extensive studies are needed to confirm the drug’s effectiveness and safety in larger populations. The researchers plan to expand the study to include more patients and report additional findings later this year.

For now, if you or someone you know is dealing with advanced cancer, it may be worth discussing emerging treatments like CTX-8371 with a healthcare provider. Staying informed about new therapies can empower you to explore all available options.

Source: globenewswire.com